bromocriptine (TW-012R) / Kyoto University, Time Therap, Towa Pharma - LARVOL DELTA

Drug discovery research with the iPSC models of neurodegenerative diseases. (PubMed, Neurosci Res) - "In addition, clinical trials based on research with iPSCs have been conducted: bosutinib, ropinirole and ezogabine for ALS, WVE-004 and BIIB078 for ALS with frontotemporal dementia (ALS/FTD), and bromocriptine for familial AD. Finally, we also wish to mention screening studies utilizing artificial intelligence (AI)."

Journal • Review • Alzheimer's Disease • Amyotrophic Lateral Sclerosis • CNS Disorders • Dementia • Frontotemporal Lobar Degeneration

REBRAnD: Repurposing Bromocriptine for Abeta Metabolism in Alzheimer's Disease (clinicaltrials.gov) - P1/2 | N=8 | Completed | Sponsor: Kyoto University | Active, not recruiting ➔ Completed | Trial completion date: Mar 2022 ➔ Nov 2021 | Trial primary completion date: Mar 2022 ➔ Nov 2021

Trial completion • Trial completion date • Trial primary completion date • Alzheimer's Disease • CNS Disorders • CSF P-tau • CSF T-tau • Plasma NfL • Plasma T-Tau

[VIRTUAL] Clinical Trial Protocol of Bromocriptine in Alzheimer’s Disease with Presenilin 1 (PSEN1) Mutations (CTAD 2021) - "This ongoing clinical trial started to enroll participants in June 2020 and will end in March 2022. This study will be conducted at 6 academic hospitals and 1 community hospital in Japan. Conclusion/ This study is the first to use bromocriptine for PSEN1-AD patients, and it presents both a low- and a high-dose safety verification as well as cognitive, neuropsychiatric and biomarker-based efficacy detections."

Clinical • Alzheimer's Disease • CNS Disorders • Dementia • Endocrine Cancer • Infectious Disease • Movement Disorders • Novel Coronavirus Disease • Oncology • Parkinson's Disease • Pituitary Gland Carcinoma • Psychiatry • Amyloid PET • CSF P-tau • CSF T-tau • Plasma NfL • Plasma T-Tau • Tau PET

REBRAnD: Repurposing Bromocriptine for Abeta Metabolism in Alzheimer's Disease (clinicaltrials.gov) - P1/2; N=8; Active, not recruiting; Sponsor: Kyoto University; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Alzheimer's Disease • CNS Disorders • CSF P-tau • CSF T-tau • Plasma NfL • Plasma T-Tau

Repurposing bromocriptine for Aβ metabolism in Alzheimer's disease (REBRAnD) study: randomised placebo-controlled double-blind comparative trial and open-label extension trial to investigate the safety and efficacy of bromocriptine in Alzheimer's disease with presenilin 1 (PSEN1) mutations. (PubMed, BMJ Open) - P1/2 | "The study results are expected to be disseminated at international or national conferences and published in international journals following the peer-review process. jRCT2041200008, NCT04413344."

Clinical • Journal • Alzheimer's Disease • CNS Disorders • Dementia

REBRAnD: Repurposing Bromocriptine for Abeta Metabolism in Alzheimer's Disease (clinicaltrials.gov) - P1/2; N=10; Recruiting; Sponsor: Kyoto University; Trial completion date: Dec 2021 ➔ Mar 2022; Trial primary completion date: Dec 2021 ➔ Mar 2022

Clinical • Trial completion date • Trial primary completion date • Alzheimer's Disease • CNS Disorders • CSF P-tau • CSF T-tau • Plasma NfL • Plasma T-Tau

REBRAnD: Repurposing Bromocriptine for Abeta Metabolism in Alzheimer's Disease (clinicaltrials.gov) - P1/2; N=10; Recruiting; Sponsor: Kyoto University; Trial completion date: Sep 2021 ➔ Dec 2021; Trial primary completion date: Sep 2021 ➔ Dec 2021

Clinical • Trial completion date • Trial primary completion date • Alzheimer's Disease • CNS Disorders • CSF P-tau • CSF T-tau • Plasma NfL • Plasma T-Tau

REBRAnD: Repurposing Bromocriptine for Abeta Metabolism in Alzheimer's Disease (clinicaltrials.gov) - P1/2; N=10; Recruiting; Sponsor: Kyoto University; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Alzheimer's Disease • CNS Disorders • CSF P-tau • CSF T-tau • Plasma NfL • Plasma T-Tau

REBRAnD: Repurposing Bromocriptine for Abeta Metabolism in Alzheimer's Disease (clinicaltrials.gov) - P1/2; N=10; Not yet recruiting; Sponsor: Kyoto University

Clinical • New P1/2 trial • Alzheimer's Disease • CNS Disorders